An observational study in Acute Respiratory Distress, sponsored by Mofid Children Hospital. Completed at 1 site in Iran. Open to participants aged 1 Month to 18 Years. Per ClinicalTrials.gov, last updated 2024-08-29.
Sponsored by Mofid Children Hospital · Observational
l Respiratory distress is still a major concern in pediatric medicine. l In this study we evaluated the symptoms and causes of respiratory distress among children in a tertiary hospital.
l We found that tachypnea is the most common symptom and asthma is the most common cause of respiratory distress in children.
994 studies on the registry are indexed under Acute Lung Injury; 156 are open to participants now.
This study's enrollment of 154 is above the median of 100 across 368 observational studies indexed under Acute Lung Injury.
Browse Acute Lung Injury studies →This is the only study on the registry with Mofid Children Hospital as lead sponsor.
Counted across the registry records on this site, refreshed daily.
From a total of 186 patients who visited the emergency room of Mofid Children's Hospital during the period of the study, 154 included in the study
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
It is a descriptive study
The most common symptom
Time frame: six months
The most common cause of respiratory distress
Time frame: six months
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.